Arrowhead Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2830 arrowheadpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals, Inc.

3 Biotech Stocks To Watch In October 2026 - Oct 9th, 2026 6:16 pm
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia - Oct 7th, 2026 5:30 am
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Sep 29th, 2026 5:30 am
RNAi drug specialist ADARx raises $446M IPO - Sep 24th, 2026 6:36 pm
ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near - Sep 24th, 2026 5:20 am
Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds - Sep 18th, 2026 10:18 pm
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress - Sep 18th, 2026 6:02 pm
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands - Sep 18th, 2026 3:02 pm
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics - Sep 18th, 2026 4:42 am
Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’ - Sep 16th, 2026 11:41 am
Arrowhead Achieves Clinical Validation for New Drug Platform - Sep 16th, 2026 5:39 am
ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move? - Sep 15th, 2026 1:03 pm
FDA clears first generic radioligand drug; Sionna turns to layoffs - Sep 15th, 2026 11:13 am
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Sep 15th, 2026 5:30 am
ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 - Sep 8th, 2026 5:07 am
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million - Sep 6th, 2026 4:15 pm
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label? - Sep 4th, 2026 10:15 am
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging. - Sep 4th, 2026 10:13 am
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences - Sep 3rd, 2026 5:30 am
Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress? - Sep 1st, 2026 5:09 am